9/29/2021 1:06:48 AM
Addex Therapeutics Begins Phase 2a Clinical Study With Dipraglurant As A Potential Treatment For Blepharospasm
9/22/2021 1:50:22 AM
CMTA And Addex Therapeutics Enter Collaboration To Advance GABA B PAM As Potential Treatment For CMT1A
6/30/2021 1:30:48 AM
Addex Therapeutics Enters Sales Agreement With Cantor Fitzgerald To Offer ADSs Through At-the-market Offering Program
6/29/2021 1:04:02 AM
Addex Therapeutics Begins Pivotal Phase 2b/3 Study Of Dipraglurant For Dyskinesia Associated With Parkinson’s Disease
6/17/2021 1:16:38 AM
Addex Therapeutics Says Shareholders Approved All Proposals Of Board In Its 2021 AGM
6/7/2021 1:03:50 AM
Addex Enrolls First Patients In Phase 2 Clinical Study Of JNJ-40411813 In Patients With Epilepsy
2/24/2021 4:14:59 AM
Enamine Extend Collaboration With Addex Therapeutics
1/21/2021 1:03:42 AM
Addex Therapeutics Receives IND Approval For ADX71149 From FDA To Start Phase 2a Clinical Study In Epilepsy
8/12/2020 1:24:07 AM
Addex Therapeutics Q2 Loss Per Share CHF 0.12 Vs Loss CHF 0.17 Last Year
4/8/2020 1:06:31 AM
Addex Therapeutics FY Loss Per Share CHF 0.56 Vs Loss CHF 0.07 Last Year